Oral fludarabine in combination with doxorubicin and dexamethasone as first-line therapy for nodal peripheral T-cell lymphomas: early results of a prospective multicenter study
- 108 Downloads
Nodal peripheral T-cell lymphomas (PTCLs) have particularly poor prognoses. Few data enabling establishment of an accepted standard treatment modality for PTCLs are available. We hypothesized that fludarabine-based regimens are tolerable and effective in treatment for nodal PTCLs. Therefore, this study was to analyze the toxicity of, response rate for, and outcome of treatment for nodal PTCLs with oral fludarabine, doxorubicin, and dexamethasone (FAD).
Patients with PTCLs received FAD every 28 days, consisting of oral fludarabine at 40 mg/m2 on days 1–3, doxorubicin at 50 mg/m2 on day 1, and oral dexamethasone at 20 mg/day on days 1–5. Patients who did not exhibit disease progression received at least four courses of treatment.
Thirty-one of 35 patients with previously untreated nodal PTCLs enrolled in the study from 2007 to 2008 were evaluable. The incidence of grade 3–4 neutropenia was 55%. Nine patients had to have dose reductions of fludarabine and doxorubicin, none of whom had grade 3 or 4 toxic effects at the lower dose. Five of 31 patients had pneumonitis. No treatment-related mortality occurred. The response rate for the entire patient population was 71%, and the complete remission rate was 48%. The PFS and OS rates at 2 years were 54.2 and 77.1%, respectively. Four patients had died of cancer progression at the time of this analysis. The serum lactate dehydrogenase level had a significant effect on PFS and OS.
The FAD regimen had encouraging efficacy with an acceptable toxicity profile in patients with nodal PTCLs.
KeywordsChemotherapy Fludarabine Peripheral T-cell Lymphoma Toxicity Survival
We thank Bayer HealthCare for support free Fludarabine for enrolled patients. We thank Mr. Norwood Donald R, who is a scientific editor of department of scientific publications from MD Anderson cancer center of the USA, for her assistance in the language writing of this article.
Conflict of interest
The authors declare that they have no conflict of interest.
- 1.Harris NL, Swerdlow S, Campo E, Jaffe ES, Stein H, Pileri S, Thiele J, Vardiman J (2008) The World Health Organization (WHO) classification of lymphoid neoplasms: what’s new? Ann Oncol 19:119Google Scholar
- 6.Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, Gianni AM, Rambaldi A, Barbui T, Cortelazzo S (2006) Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20(9):1533–1538PubMedCrossRefGoogle Scholar
- 8.Feyler S, Prince H, Pearce R (2007) The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study Bone Marrow Transplant 40:443–450Google Scholar
- 12.Rossi JF, van Hoof A, de Boeck K, Johnson SA, Bron D, Foussard C, Lister TA, Berthou C, Kramer MH, Littlewood TJ, Marcus RE, Deconinck E, Montillo M, Guibon O, Tollerfield SM (2004) Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 22(7):1260–1267PubMedCrossRefGoogle Scholar
- 13.Tobinai K, Watanabe T, Ogura M, Morishima Y, Ogawa Y, Ishizawa K, Minami H, Utsunomiya A, Taniwaki M, Terauchi T, Nawano S, Matsusako M, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Hayashi M, Seriu T, Hotta T (2006) Phase II study of oral fludarabine phosphate in relapsed indolent B-Cell non-Hodgkin’s lymphoma. J Clin Oncol 24(1):174–180PubMedCrossRefGoogle Scholar
- 14.Damaraju D, Damaraju VL, Brun M, Mowles D, Kuzma M, Berendt RC, Sawyer MB, Cass CE (2008) Cytotoxic activities of nucleoside and nucleobase analog drugs in malignant mesothelioma: characterization of a novel nucleobase transport activity. Biochem Pharmacol 75(10):1901–1911PubMedCrossRefGoogle Scholar
- 16.Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD (2008) ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK + ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 111(12):5496–5504PubMedCrossRefGoogle Scholar
- 17.Coiffier B, Brousse N, Peuchmaur M, Berger F, Gisselbrecht C, Bryon PA, Diebold J (1990) Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d’Etude des Lymphomes Agressives). Ann Oncol 1(1):45–50PubMedGoogle Scholar
- 21.Vose JM (2008) Peripheral T-cell non-Hodgkin’s lymphoma. Hematol Oncol Clin North Am 22(5):997–1005, xGoogle Scholar
- 22.Savage K, Ferreri AJ, Zinzani PL, Pileri SA (2010) Peripheral T-cell lymphoma—not otherwise specified. Crit Rev Oncol Hematol. doi: 10.1016/j.critrevonc.2010.07.007
- 26.Arkenau HT, Chong G, Cunningham D, Watkins D, Sirohi B, Chau I, Wotherspoon A, Norman A, Horwich A, Matutes E (2007) Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience. Haematologica 92(2):271–272PubMedCrossRefGoogle Scholar
- 27.de Totero D, Tazzari PL, Capaia M, Montera MP, Clavio M, Balleari E, Foa R, Gobbi M (2003) CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation. Haematologica 88(2):148–158PubMedGoogle Scholar
- 30.Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L, Estany C, Camos M, Colomo L, Espinosa I, Martinez S, Ribera JM, Martino R, Gutierrez-Garcia G, Montserrat E, Lopez-Guillermo A (2008) Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19(5):958–963PubMedCrossRefGoogle Scholar
- 32.Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, Levis A, Manna A, Secondo V, Rigacci L, Pinto A, Iannitto E, Zoli V, Torchio P, Pileri S, Tarella C (2007) Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110(7):2316–2323PubMedCrossRefGoogle Scholar
- 35.Takamatsu Y, Suzumiya J, Utsunomiya A, Maeda K, Matsuoka H, Suzushima H, Tsukada J, Shibata K, Tamura K (2010) THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study. Eur J Haematol 84(5):391–397Google Scholar